While great progress has been achieved in the clinical management and molecular understanding of Ph+ chronic myeloid leukemia (CML), little is known about the optimal approach to monitor and treat patients with ETV6-ABL1 + myeloproliferative neoplasms. Nine BCR-ABL1-negative CML patients with a variant ABL1 gene (9q34) rearrangement, involving fusion to ETV6 aka TEL (12p13) have been reported thus far. [1] [2] [3] [4] [5] [6] [7] [8] [9] The ETV6-ABL1 fusion gene has also been identified in 3 patients with chronic myeloproliferative neoplasms other than "chronic myeloid leukemia" (cMPN) as well as 7 patients with BCR-ABL1 negative acute lymphoblastic leukemia and 4 patients with acute myeloid leukemia. 10, 11 Of the 9 cases of ETV6-ABL1 + chronic myeloid leukemia, only 2 were treated with a TKI in chronic phase 4, 5 and only one of these reached a complete remission with a modest follow up of seven months (no molecular monitoring was performed). 4 Among the other published ETV6-ABL1 + reports, one patient was treated with a second generation TKI for a relapsed cMPN. 12 We provide the first molecular documentation of sustained remission of ETV6-ABL1 + chronic phase "chronic myeloid leukemia" (CML requires a BCR-ABL1 fusion according to the most recent 2008 WHO classification) to TKI. Molecular monitoring for the ETV6-ABL1 transcript is important given the fact that conventional karyotyping frequently fails to detect a cryptic translocation, i.e. the t(9;12). We provide evidence that treatment of ETV6-ABL1+ "chronic myeloid leukemia" with imatinib results in downregulation of C-MYC, BCL-XL, ID1 and NUP98, mediators of BCR-ABL1 transforming activity. Moreover, we found no associated mutations in UTX, ASXL1, EZH2, TET2 and IDH1/2 suggesting that ETV6-ABL1 + "chronic myeloid leukemia" may be as tyrosine kinase focused as BCR-ABL1 driven disease.
The patient is a 36-year male who was found to have splenomegaly and a total white blood cell (WBC) count of 55¥10 9 /L (57% neutrophils, 6% lymphocytes, 1% monocytes, 3% eosinophils, 2% basophils, 7% metamyelocytes, 24% myelocytes). Lactate dehydrogenase was elevated at 653 IU/L. Bone marrow biopsy revealed myeloid hyperplasia suggestive of a myeloproliferative disorder. qRT-PCR for BCR-ABL1 translocation was negative. No BCR-ABL1 fusion signal was observed in interphase FISH analysis using BCR (22q11.2) and ASS-ABL1 (9q34) probes. Instead, 80% of interphase nuclei showed a variant signal pattern consisting of two signals for BCR and three signals for ASS-ABL1 consistent with rearrangement of ABL1 at 9q34 but not BCR at 22q11. Cytogenetic G-banding analysis and FISH showed t(9;12)(q34;p13) in an otherwise normal karyotype ( Figure 1A and B) . RT-PCR detected the ETV6-ABL1 translocation and the patient was diagnosed with ETV6-ABL1 + CML-like disorder. Given the persistence of night sweats and fevers, and the persistent disease despite hydroxyurea at 1,000mg daily (WBC decreased to 7¥10 9 cells/L after one month of hydroxyurea) imatinib mesylate, 400mg daily, was initiated. The patient tolerated imatinib and achieved a complete hematological remission after three months of treatment (WBC 5.6¥10 9 cells/L). FISH testing after three months of imatinib revealed no evidence of rearrangement at the BCR or ETV6 loci ( Figure 1B) .
To follow the patient's response to therapy more sensitively, qRT-PCR was performed using primers for ETV6 and ABL1 (Online Supplementary  Appendix) . Quantification of the ETV6-ABL1 transcript level in peripheral blood cells one month prior to initiation of imatinib revealed 2,160¥10 3 ETV6-ABL1 copies/μg RNA. After one month of treatment, ETV6-ABL1 transcript level dropped to 495¥10 3 copies/μg RNA. The ETV6-ABL1 transcript became undetectable by seven months of treatment, indicating a complete and rapid molecular response. The patient's molecular response closely mirrored normalization of the WBC count (Figure 2A 
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Pre-imatinib Post-imatinib BCR-ABL 1 probe 9 12 ETV6-AML probe do well on imatinib 400mg/day with no evidence of ETV6-ABL1 transcript by qRT-PCR for the past five years. Somatic mutations in UTX, ASXL1, and TET2 have been reported in chronic myeloid leukemia and mutations in EZH2 and IDH1/2 in myeloid malignancies other than CML. We found no somatic alterations in these genes in the DNA extracted from whole blood prior to imatinib treatment, nor when the patient was in a molecular remission.
Our studies indicate that ETV6-ABL1 + "chronic myeloid leukemia" can be sensitive to imatinib and there is significant overlap of molecular targets of ETV6-ABL1 with those of BCR-ABL1, suggesting that the ETV6-ABL1 fusion protein may trigger similar oncogenic cascades as BCR-ABL1. Finally, we were able to exclude mutations in any of the recently identified "myeloid" genes including UTX, ASXL1, EZH2, TET2 and IDH1/2 suggesting that the pathogenesis of ETV6-ABL1 + "chronic myeloid leukemia" may be as tyrosine kinase focused as BCR-ABL1 driven disease. Letters to the Editor 
